Author

Pier Adelchi Ruffini

Observed names: P A Ruffini, P Ruffini, P. A. Ruffini, P. Ruffini, P.A Ruffini, PIER A. RUFFINI, Pier A Ruffini, Pier A. Ruffini, Pier Ruffini, Ruffini Pier Adelchi, Ruffini, Pier

Institution: Dompé (Italy)

Observed institutions: Oslo University Hospital, National Institutes of Health, University of Oslo, University of Milan, Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda, Philogen (Italy), Frederick National Laboratory for Cancer Research, National Cancer Institute, Dompé (Italy), Center for Cancer Research, Fondazione IRCCS Istituto Nazionale dei Tumori

ORCID: 0000-0001-9492-9627

Observed ORCID: 0000-0001-9492-9627

OpenAlex ID: A5030609859

Toll-Like Receptor 4-Dependent Activation of Dendritic Cells by β-Defensin 2

2002 · Arya Biragyn, Pier Adelchi Ruffini, et al. · Science · 914

Mediators of Innate Immunity That Target Immature, But Not Mature, Dendritic Cells Induce Antitumor Immunity When Genetically Fused with Nonimmunogenic Tumor Antigens

2001 · Arya Biragyn, Munhsuren Surenhu, et al. · The Journal of Immunology · 284

Phase Ib Pilot Study to Evaluate Reparixin in Combination with Weekly Paclitaxel in Patients with HER-2–Negative Metastatic Breast Cancer

2017 · Anne F. Schott, Lori J. Goldstein, et al. · Clinical Cancer Research · 257

Intratumoural FOXP3-positive regulatory T cells are associated with adverse prognosis in radically resected gastric cancer

2008 · Giuseppe Perrone, Pier Adelchi Ruffini, et al. · European Journal of Cancer · 218

CXCR1/2 inhibition enhances pancreatic islet survival after transplantation

2012 · Antonio Citro, Elisa Cantarelli, et al. · Journal of Clinical Investigation · 149

A window-of-opportunity trial of the CXCR1/2 inhibitor reparixin in operable HER-2-negative breast cancer

2020 · Lori J. Goldstein, Raymond P. Perez, et al. · Breast Cancer Research · 135

PDF

Manipulating the chemokine‐chemokine receptor network to treat cancer

2007 · Pier A. Ruffini, Paolo Morandi, et al. · Cancer · 114

A randomized, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for metastatic triple-negative breast cancer (fRida)

2021 · Lori J. Goldstein, Mauro Mansutti, et al. · Breast Cancer Research and Treatment · 104

PDF

Intralesional Treatment of Stage III Metastatic Melanoma Patients with L19–IL2 Results in Sustained Clinical and Systemic Immunologic Responses

2014 · Benjamin Weide, Thomas K. Eigentler, et al. · Cancer Immunology Research · 100

CXCR1/2 Inhibition Blocks and Reverses Type 1 Diabetes in Mice

2014 · Antonio Citro, Andrea Valle, et al. · Diabetes · 95

Targeting CXCR1 on breast cancer stem cells: signaling pathways and clinical application modelling

2015 · Laura Brandolini, Loredana Cristiano, et al. · Oncotarget · 83

Safety and Pharmacokinetics of Escalating Doses of Human Recombinant Nerve Growth Factor Eye Drops in a Double-Masked, Randomized Clinical Trial

2013 · Mauro P. Ferrari, Flavio Mantelli, et al. · BioDrugs · 78

PDF

Loco-regional immunotherapy with recombinant interleukin-2 and adherent lymphokine-activated killer cells (A-LAK) in recurrent glioblastoma patients

1994 · Amerigo Boiardi, Antonio Silvani, et al. · Cancer Immunology Immunotherapy · 74

Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines.

2002 · Pier Adelchi Ruffini, Sattva S Neelapu, et al. · PubMed · 64

The CXCL8-CXCR1/2 Axis as a Therapeutic Target in Breast Cancer Stem-Like Cells

2019 · Pier Adelchi Ruffini · Frontiers in Oncology · 61

PDF

Factors, including transforming growth factor β, released in the glioblastoma residual cavity, impair activity of adherent lymphokine-activated killer cells

1993 · Pier Adelchi Ruffini, Licia Rivoltini, et al. · Cancer Immunology Immunotherapy · 61

CXCR1/2 pathways in paclitaxel-induced neuropathic pain

2017 · Brandolini Laura, Benedetti Elisabetta, et al. · Oncotarget · 60

Ladarixin, an inhibitor of the interleukin‐8 receptors CXCR1 and CXCR2 , in new‐onset type 1 diabetes: A multicentre, randomized, double‐blind, placebo‐controlled trial

2022 · Lorenzo Piemonti, Bart Keymeulen, et al. · Diabetes Obesity and Metabolism · 55

PDF

Chemokine receptor-mediated delivery directs self-tumor antigen efficiently into the class II processing pathway in vitro and induces protective immunity in vivo

2004 · A. Biragyn, Pier Adelchi Ruffini, et al. · Blood · 53

PDF

Targeting CXCR1/2 Does Not Improve Insulin Secretion After Pancreatic Islet Transplantation: A Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial in Type 1 Diabetes

2020 · Paola Maffi, Torbjörn Lundgren, et al. · Diabetes Care · 51

Prognostic role of human equilibrative transporter 1 (hENT1) in patients with resected gastric cancer

2010 · Daniele Santini, Bruno Vincenzi, et al. · Journal of Cellular Physiology · 45

Human chemokine MIP1α increases efficiency of targeted DNA fusion vaccines

2010 · Pier Adelchi Ruffini, Gunnveig Grødeland, et al. · Vaccine · 37

Armed antibodies for cancer treatment: a promising tool in a changing era

2014 · Riccardo Danielli, Roberto Patuzzo, et al. · Cancer Immunology Immunotherapy · 34

Genetic fusions with viral chemokines target delivery of nonimmunogenic antigen to trigger antitumor immunity independent of chemotaxis

2004 · Pier Adelchi Ruffini, Arya Biragyn, et al. · Journal of Leukocyte Biology · 34

Review: To What Extent are T Cells Tolerant to Immunoglobulin Variable Regions?

2009 · B. Bogen, P. Ruffini · Scandinavian Journal of Immunology · 31

PDF

Works count: 72

Citation count: 3,422

H-index: 26

I10-index: 34